GlassScriptPhysician profile
Sandra J Day
NPI 1346364841
$1,445.90
in general payments reported to CMS, 2019-2025
15 companies · $36.54 in 2025
The $36.54 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $387 · 2023: $785 · 2024: $122 · 2025: $36.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $628.55 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $123.00 | 2022-2023 | Gardasil 9, Delstrigo, Dificid |
| Pfizer INC. | $118.90 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $116.21 | 2021-2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $90.72 | 2022 | |
| Novo Nordisk INC | $61.12 | 2022-2024 | Wegovy, Saxenda |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.93 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $51.29 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $49.57 | 2023 | Repatha, Otezla |
| Abbott Laboratories | $35.89 | 2022 | |
| Alk-Abello, INC | $32.54 | 2023 | Grastek, Odactra, Ragwitek |
| Bayer Healthcare Pharmaceuticals INC. | $26.74 | 2022-2023 | |
| Theratechnologies INC. | $24.57 | 2023 | Egrifta, Trogarzo |
| Glaxosmithkline, LLC. | $17.75 | 2024 | Trelegy Ellipta |
| Grt US Holding, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.